QrumPharma

QrumPharma develops inhaled therapies for the treatment of severe chronic and recurrent pulmonary diseases, including non-tuberculous mycobacterial (NTM) lung disease. The experienced team of drug development professionals at QrumPharma has a long track record of successfully developing treatments for pulmonary diseases and possesses technical, clinical, and regulatory expertise to reduce development risks and minimize development time.